Xspray Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Xspray Pharma hat ein Gesamteigenkapital von SEK585.6M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK667.7M bzw. SEK82.1M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 74.76m
Eigenkapital	SEK 585.59m
Gesamtverbindlichkeiten	SEK 82.10m
Gesamtvermögen	SEK 667.70m

Jüngste Berichte zur Finanzlage

Recent updates

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Feb 25

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

May 11

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Feb 01

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Oct 26

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Jun 20

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Mar 19

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Feb 12

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Dec 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: XSPRAYDie kurzfristigen Aktiva des Unternehmens (SEK101.5M) übersteigen seine kurzfristigen Passiva (SEK53.5M).

Langfristige Verbindlichkeiten: XSPRAYDie kurzfristigen Vermögenswerte des Unternehmens (SEK101.5M) übersteigen seine langfristigen Verbindlichkeiten (SEK28.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: XSPRAY ist schuldenfrei.

Schulden abbauen: XSPRAY hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: XSPRAY verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 4 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass XSPRAY auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 6 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Xspray Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

New major risk - Financial position

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127